Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma

Ajjai Alva, Gregory A. Daniels, Michael K K Wong, Howard L. Kaufman, Michael A. Morse, David F. McDermott, Joseph I. Clark, Sanjiv S. Agarwala, Gerald Miletello, Theodore Logan, Ralph J. Hauke, Brendan Curti, John M. Kirkwood, Rene Gonzalez, Asim Amin, Mayer Fishman, Neeraj Agarwal, James N. Lowder, Hong Hua, Sandra Aung & 1 others Janice P. Dutcher

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

High-dose interleukin-2 (HD IL-2) was approved for treatment of metastatic renal cell carcinoma (mRCC) in 1992 and for metastatic melanoma (mM) in 1998, in an era predating targeted therapies and immune checkpoint inhibitors. The PROCLAIMSM registry was established to collect and analyze data for patients treated with HD IL-2 in the current era. This analysis includes 170 patients with mM and 192 patients with mRCC treated between 2005 and 2012 with survival data current as of July 27, 2015. For patients with mM, complete response (CR) was observed in 5 %, partial response (PR) in 10 %, stable disease (SD) in 22 %, and 63 % had progressive disease (PD). The median overall survival (mOS) for these patients was 19.6 months, with a median follow-up of 43.1 months. The mOS was not reached for patients achieving CR or PR, and was 33.4 months for patients with SD. For patients with mRCC, 6 % achieved CR, 9 % had PR, 22 % had SD, and 62 % had PD. The mOS was 41 months, with a median follow-up of 46.6 months. The mOS for patients who had CR and PR was not reached and was 49.6 months for patients with SD. There were no treatment-related deaths among 362 patients. The duration of mOS for patients with mM and mRCC is longer than historically reported. These data support a continued role for IL-2 in the treatment of eligible patients with mM or mRCC and warrant further evaluation of HD IL-2 in combination or sequence with other therapeutic agents.

Original languageEnglish (US)
Pages (from-to)1-12
Number of pages12
JournalCancer Immunology and Immunotherapy
DOIs
StateAccepted/In press - Oct 6 2016

Fingerprint

Renal Cell Carcinoma
Interleukin-2
Melanoma
Survival
Therapeutics
Registries

Keywords

  • Immunotherapy
  • Interleukin-2
  • Melanoma
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. / Alva, Ajjai; Daniels, Gregory A.; Wong, Michael K K; Kaufman, Howard L.; Morse, Michael A.; McDermott, David F.; Clark, Joseph I.; Agarwala, Sanjiv S.; Miletello, Gerald; Logan, Theodore; Hauke, Ralph J.; Curti, Brendan; Kirkwood, John M.; Gonzalez, Rene; Amin, Asim; Fishman, Mayer; Agarwal, Neeraj; Lowder, James N.; Hua, Hong; Aung, Sandra; Dutcher, Janice P.

In: Cancer Immunology and Immunotherapy, 06.10.2016, p. 1-12.

Research output: Contribution to journalArticle

Alva, A, Daniels, GA, Wong, MKK, Kaufman, HL, Morse, MA, McDermott, DF, Clark, JI, Agarwala, SS, Miletello, G, Logan, T, Hauke, RJ, Curti, B, Kirkwood, JM, Gonzalez, R, Amin, A, Fishman, M, Agarwal, N, Lowder, JN, Hua, H, Aung, S & Dutcher, JP 2016, 'Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma', Cancer Immunology and Immunotherapy, pp. 1-12. https://doi.org/10.1007/s00262-016-1910-x
Alva, Ajjai ; Daniels, Gregory A. ; Wong, Michael K K ; Kaufman, Howard L. ; Morse, Michael A. ; McDermott, David F. ; Clark, Joseph I. ; Agarwala, Sanjiv S. ; Miletello, Gerald ; Logan, Theodore ; Hauke, Ralph J. ; Curti, Brendan ; Kirkwood, John M. ; Gonzalez, Rene ; Amin, Asim ; Fishman, Mayer ; Agarwal, Neeraj ; Lowder, James N. ; Hua, Hong ; Aung, Sandra ; Dutcher, Janice P. / Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. In: Cancer Immunology and Immunotherapy. 2016 ; pp. 1-12.
@article{ee7530fe834c4b039e5835e1ce3df565,
title = "Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma",
abstract = "High-dose interleukin-2 (HD IL-2) was approved for treatment of metastatic renal cell carcinoma (mRCC) in 1992 and for metastatic melanoma (mM) in 1998, in an era predating targeted therapies and immune checkpoint inhibitors. The PROCLAIMSM registry was established to collect and analyze data for patients treated with HD IL-2 in the current era. This analysis includes 170 patients with mM and 192 patients with mRCC treated between 2005 and 2012 with survival data current as of July 27, 2015. For patients with mM, complete response (CR) was observed in 5 {\%}, partial response (PR) in 10 {\%}, stable disease (SD) in 22 {\%}, and 63 {\%} had progressive disease (PD). The median overall survival (mOS) for these patients was 19.6 months, with a median follow-up of 43.1 months. The mOS was not reached for patients achieving CR or PR, and was 33.4 months for patients with SD. For patients with mRCC, 6 {\%} achieved CR, 9 {\%} had PR, 22 {\%} had SD, and 62 {\%} had PD. The mOS was 41 months, with a median follow-up of 46.6 months. The mOS for patients who had CR and PR was not reached and was 49.6 months for patients with SD. There were no treatment-related deaths among 362 patients. The duration of mOS for patients with mM and mRCC is longer than historically reported. These data support a continued role for IL-2 in the treatment of eligible patients with mM or mRCC and warrant further evaluation of HD IL-2 in combination or sequence with other therapeutic agents.",
keywords = "Immunotherapy, Interleukin-2, Melanoma, Renal cell carcinoma",
author = "Ajjai Alva and Daniels, {Gregory A.} and Wong, {Michael K K} and Kaufman, {Howard L.} and Morse, {Michael A.} and McDermott, {David F.} and Clark, {Joseph I.} and Agarwala, {Sanjiv S.} and Gerald Miletello and Theodore Logan and Hauke, {Ralph J.} and Brendan Curti and Kirkwood, {John M.} and Rene Gonzalez and Asim Amin and Mayer Fishman and Neeraj Agarwal and Lowder, {James N.} and Hong Hua and Sandra Aung and Dutcher, {Janice P.}",
year = "2016",
month = "10",
day = "6",
doi = "10.1007/s00262-016-1910-x",
language = "English (US)",
pages = "1--12",
journal = "Cancer Immunology, Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",

}

TY - JOUR

T1 - Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma

AU - Alva, Ajjai

AU - Daniels, Gregory A.

AU - Wong, Michael K K

AU - Kaufman, Howard L.

AU - Morse, Michael A.

AU - McDermott, David F.

AU - Clark, Joseph I.

AU - Agarwala, Sanjiv S.

AU - Miletello, Gerald

AU - Logan, Theodore

AU - Hauke, Ralph J.

AU - Curti, Brendan

AU - Kirkwood, John M.

AU - Gonzalez, Rene

AU - Amin, Asim

AU - Fishman, Mayer

AU - Agarwal, Neeraj

AU - Lowder, James N.

AU - Hua, Hong

AU - Aung, Sandra

AU - Dutcher, Janice P.

PY - 2016/10/6

Y1 - 2016/10/6

N2 - High-dose interleukin-2 (HD IL-2) was approved for treatment of metastatic renal cell carcinoma (mRCC) in 1992 and for metastatic melanoma (mM) in 1998, in an era predating targeted therapies and immune checkpoint inhibitors. The PROCLAIMSM registry was established to collect and analyze data for patients treated with HD IL-2 in the current era. This analysis includes 170 patients with mM and 192 patients with mRCC treated between 2005 and 2012 with survival data current as of July 27, 2015. For patients with mM, complete response (CR) was observed in 5 %, partial response (PR) in 10 %, stable disease (SD) in 22 %, and 63 % had progressive disease (PD). The median overall survival (mOS) for these patients was 19.6 months, with a median follow-up of 43.1 months. The mOS was not reached for patients achieving CR or PR, and was 33.4 months for patients with SD. For patients with mRCC, 6 % achieved CR, 9 % had PR, 22 % had SD, and 62 % had PD. The mOS was 41 months, with a median follow-up of 46.6 months. The mOS for patients who had CR and PR was not reached and was 49.6 months for patients with SD. There were no treatment-related deaths among 362 patients. The duration of mOS for patients with mM and mRCC is longer than historically reported. These data support a continued role for IL-2 in the treatment of eligible patients with mM or mRCC and warrant further evaluation of HD IL-2 in combination or sequence with other therapeutic agents.

AB - High-dose interleukin-2 (HD IL-2) was approved for treatment of metastatic renal cell carcinoma (mRCC) in 1992 and for metastatic melanoma (mM) in 1998, in an era predating targeted therapies and immune checkpoint inhibitors. The PROCLAIMSM registry was established to collect and analyze data for patients treated with HD IL-2 in the current era. This analysis includes 170 patients with mM and 192 patients with mRCC treated between 2005 and 2012 with survival data current as of July 27, 2015. For patients with mM, complete response (CR) was observed in 5 %, partial response (PR) in 10 %, stable disease (SD) in 22 %, and 63 % had progressive disease (PD). The median overall survival (mOS) for these patients was 19.6 months, with a median follow-up of 43.1 months. The mOS was not reached for patients achieving CR or PR, and was 33.4 months for patients with SD. For patients with mRCC, 6 % achieved CR, 9 % had PR, 22 % had SD, and 62 % had PD. The mOS was 41 months, with a median follow-up of 46.6 months. The mOS for patients who had CR and PR was not reached and was 49.6 months for patients with SD. There were no treatment-related deaths among 362 patients. The duration of mOS for patients with mM and mRCC is longer than historically reported. These data support a continued role for IL-2 in the treatment of eligible patients with mM or mRCC and warrant further evaluation of HD IL-2 in combination or sequence with other therapeutic agents.

KW - Immunotherapy

KW - Interleukin-2

KW - Melanoma

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84990837305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990837305&partnerID=8YFLogxK

U2 - 10.1007/s00262-016-1910-x

DO - 10.1007/s00262-016-1910-x

M3 - Article

SP - 1

EP - 12

JO - Cancer Immunology, Immunotherapy

JF - Cancer Immunology, Immunotherapy

SN - 0340-7004

ER -